Fluticasone furoate/vilanterol

Fluticasone furoate/vilanterol
Combination of
Fluticasone furoate	Corticosteroid
Vilanterol	Long acting β₂-agonist
Clinical data
Trade names	Breo Ellipta, Relvar Ellipta
AHFS/Drugs.com	entry
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Inhalation
Identifiers
ATC code	R03AK10

Fluticasone furoate/vilanterol (trade name Breo Ellipta in the US and Relvar Ellipta in Europe) is a combination drug for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains fluticasone furoate, a corticosteroid, and vilanterol, a long acting β₂-agonist.

In 2013, the drug was approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema,^[1] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma.^[2]

There are; however, concerns that LABAs such as vilanterol increase the risk of deaths due to asthma.^[1]

References

1 2 "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. 10 May 2013.
↑ "Summary of opinion: Relvar Ellipta" (PDF). European Medicines Agency. 19 September 2013.

Drugs for obstructive airway diseases: asthma/COPD (R03)

Adrenergics, inhalants

Short-acting β₂ agonists	Bitolterol Carbuterol Fenoterol Pirbuterol Procaterol Reproterol Rimiterol Salbutamol (albuterol)^#/Levosalbutamol (levalbuterol) Terbutaline Tulobuterol

Long-acting β₂ agonists (LABA)	Bambuterol Clenbuterol Formoterol/Arformoterol Salmeterol Salmefamol

Ultra-long-acting β₂ agonists	Indacaterol Olodaterol Vilanterol

Other	Epinephrine^# Hexoprenaline Isoprenaline (isoproterenol) Orciprenaline (metaproterenol)

Glucocorticoids

Anticholinergics/
muscarinic antagonist

Mast cell stabilizers

Xanthines

Eicosanoid inhibition

Leukotriene antagonists	Montelukast Pranlukast Zafirlukast

Arachidonate 5-lipoxygenase inhibitors	Baicalein^§ Caffeic acid^§ Curcumin^§ Hyperforin^§ Meclofenamate sodium^§ St John's wort^§ Zileuton

Thromboxane receptor antagonists	Ramatroban Seratrodast

Non-xanthine PDE4 inhibitors	Ibudilast Roflumilast

Others/unknown

Combination products

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Wednesday, May 06, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.